β-Secretase as a Therapeutic Target for Alzheimer's Disease

161Citations
Citations of this article
103Readers
Mendeley users who have this article in their library.

Abstract

β-Secretase (memapsin 2, BACE1) is an attractive target for the development of inhibitor drugs to treat Alzheimer's disease (AD). Not only does this protease function at the first step in the pathway leading to the production of amyloid-β (Aβ), its gene deletion produces only mild phenotypes. In addition, β-secretase is an aspartic protease whose mechanism and inhibition are well known. The development of β-secretase inhibitors, actively pursued over the last seven years, has been slow, due to the difficulty in combining the required properties in a single inhibitor molecule. Steady progress in this field, however, has brought about inhibitors that contain many targeted characteristics. In this review, we describe the strategy of structure-based inhibitor evolution in the development of β-secretase inhibitor drug. The current status of the field offers grounds for some optimism, in that β-secretase inhibitors have been shown to reduce brain Aβ and to rescue the cognitive decline in transgenic AD mice, and an orally available β-secretase inhibitor drug candidate is in clinical trial. With this knowledge base, it seems reasonable to expect that more drug candidates will be tested in human, and then successful disease-modifying drugs may ultimately emerge from this target. © 2008 The American Society for Experimental NeuroTherapeutics, Inc.

Cite

CITATION STYLE

APA

Ghosh, A. K., Gemma, S., & Tang, J. (2008). β-Secretase as a Therapeutic Target for Alzheimer’s Disease. Neurotherapeutics, 5(3), 399–408. https://doi.org/10.1016/j.nurt.2008.05.007

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free